Researchers sought to determine factors that may impact infection risk in patients with CLL.
Researchers sought to determine whether adding daratumumab to standard care for patients with multiple myeloma was a cost-effective option.
Researchers sought to determine whether cambinol would have antitumor activity in multiple myeloma cells.
Researchers sought to determine whether dasatinib and nilotinib would be effective second-line therapies for patients with chronic phase CML.
Researchers sought to determine whether molecular characteristics could help predict responses to treatments with venetoclax in patients with relapsed or refractory AML.
Researchers sought to determine whether paroxysmal nocturnal hemoglobinuria clones might predict treatment responses for patients with MDS and aplastic anemia.
Researchers sought to determine if immunotherapy including blinatumomab could improve disease-free survival for patients with B-cell ALL.
Study authors retrospectively evaluated effect of thymoglobulin addition in RIC and MAC regimens on the cumulative incidence and severity of acute and chronic GVHD, overall survival, and relapse rate in adult AML patients who underwent URD PBSCT.
A team of investigators evaluated the effect of measurable residual disease at time of allogeneic hematopoietic cell transplantation in patients with ALL undergoing transplantation during either first or second complete remission.
A multicenter, prospective cohort study was conducted to compare mortality and complication rates associated with cancer surgery between low-income, middle-income, and high-income countries.
